Generalized fixed drug eruption following <scp>Pfizer‐BioNtech COVID</scp>‐19 vaccination

Bullous fixed-drug eruption (FDE) is a rare but potentially severe cutaneous drug reaction that presents with erythema, edema, and bullae formation. FDE lesions are often caused by drugs such as antibiotics, anticonvulsants, and nonsteroidal anti-inflammatory drugs. The diagnosis of FDE is primarily clinical and may be supported by histopathological examination. Treatment for FDE lesions involves immediate discontinuation of the offending drug and supportive care, including topical and systemic corticosteroids. There is growing evidence to suggest that both COVID-19 and its vaccination can induce skin reactions. We report a case of a 14-year-old girl who developed a bullous FDE lesion following an anti-COVID-19 SARS-CoV-2 immunization.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Generalized fixed drug eruption following Pfizer‐BioNtech COVID‐19 vaccination

Cited by 2 publications

References 9 publications

Polysensitive radiation recall dermatitis following Prevnar 20 vaccination

Polysensitive radiation recall dermatitis following Prevnar 20 vaccination

Fixed-drug eruption following first dose of SARS-CoV-2 (COVID-19) vaccine approved for children, an adverse event following immunization

Contact Info

Product

Resources

About